Please find enclosed the Investor Presentation on the Audited Financial Results for the quarter and financial year ended on March 31, 2026.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies reported strong Q4FY26 results with consolidated revenue of ₹224 crore (+20% YoY) and EBITDA of ₹75 crore (+31% YoY), with EBITDA margin expanding to 34% from 31% in Q4FY25. For full year FY26, revenue grew 21% to ₹829 crore while EBITDA jumped 38% to ₹262 crore with margin improving to 32% from 28% in FY25. PAT more than doubled in Q4 (+128% YoY) and grew 81% for FY26 to ₹163 crore. Operationally, tests conducted increased 23% to 209.6 million, active franchisees reached a record ~10,800 (+15% YoY), and the test menu expanded to 1,275 tests (+39% YoY) with new technologies like Next Gen sequencing and ImmunoCAP. Tanzania operations were fully consolidated as a subsidiary during the year.
The company demonstrated consistent margin expansion and strong profitability growth, indicating operational leverage from its franchise network expansion and test menu diversification. The 25% CAGR in franchisee count since FY21 shows sustainable network growth, while the new brand ambassador (Madhuri Dixit) and national awards strengthen brand positioning.